0000950170-23-011909.txt : 20230405 0000950170-23-011909.hdr.sgml : 20230405 20230405161021 ACCESSION NUMBER: 0000950170-23-011909 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230330 ITEM INFORMATION: Other Events FILED AS OF DATE: 20230405 DATE AS OF CHANGE: 20230405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rani Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001856725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40672 FILM NUMBER: 23802625 BUSINESS ADDRESS: STREET 1: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 BUSINESS PHONE: (408) 457-3700 MAIL ADDRESS: STREET 1: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 8-K 1 rani-20230330.htm 8-K 8-K
0001856725false00018567252023-03-302023-03-30

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

March 30, 2023

 

 

Rani Therapeutics Holdings, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40672

86-3114789

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2051 Ringwood Avenue

 

San Jose, California

 

95131

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (408) 457-3700

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Class A common stock, par value $0.0001 per share

 

RANI

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 30, 2023, Ms. Lyn Baranowski notified Rani Therapeutics Holdings, Inc. (the “Company”) that she does not intend to stand for re-election at the 2023 annual meeting of stockholders of the Company (“Annual Meeting”). Accordingly, Ms. Baranowski will cease to be a member of the Board of Directors of the Company and the Compensation Committee and the Nominating and Corporate Governance Committee thereof, effective as of the date of the Annual Meeting. Ms. Baranowski’s decision to not stand for re-election is not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

Rani Therapeutics Holdings, Inc.

 

 

 

 

Date:

April 5, 2023

By:

/s/ Svai Sanford

 

 

 

Svai Sanford
Chief Financial Officer

 

 EX-101.SCH 2 rani-20230330.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 3 rani-20230330_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 rani-20230330_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Mar. 30, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 30, 2023
Entity Registrant Name Rani Therapeutics Holdings, Inc.
Entity Central Index Key 0001856725
Entity Emerging Growth Company true
Securities Act File Number 001-40672
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 86-3114789
Entity Address, Address Line One 2051 Ringwood Avenue
Entity Address, City or Town San Jose
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95131
City Area Code (408)
Local Phone Number 457-3700
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Class A common stock, par value $0.0001 per share
Trading Symbol RANI
Security Exchange Name NASDAQ
XML 6 rani-20230330_htm.xml IDEA: XBRL DOCUMENT 0001856725 2023-03-30 2023-03-30 0001856725 false 8-K 2023-03-30 Rani Therapeutics Holdings, Inc. DE 001-40672 86-3114789 2051 Ringwood Avenue San Jose CA 95131 (408) 457-3700 N/A false false false false Class A common stock, par value $0.0001 per share RANI NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports rani-20230330.htm rani-20230330.xsd rani-20230330_lab.xml rani-20230330_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rani-20230330.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "rani-20230330.htm" ] }, "labelLink": { "local": [ "rani-20230330_lab.xml" ] }, "presentationLink": { "local": [ "rani-20230330_pre.xml" ] }, "schema": { "local": [ "rani-20230330.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rani", "nsuri": "http://www.ranitherapeutics.com/20230330", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rani-20230330.htm", "contextRef": "C_e0aa130c-47d6-4ae1-aa25-966d72edd7f0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rani-20230330.htm", "contextRef": "C_e0aa130c-47d6-4ae1-aa25-966d72edd7f0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ranitherapeutics.com/20230330/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0000950170-23-011909-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-011909-xbrl.zip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end